Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code is needed.
Back to School Savings: Save up to 30% on print books and eBooks. No promo code needed.
Back to School Savings: Save up to 30%
Transcription and Translation in Health and Disease
1st Edition - January 30, 2023
Editors: Manoj Garg, Gautam Sethi, Amit Kumar Pandey
Paperback ISBN:
9 7 8 - 0 - 3 2 3 - 9 9 5 2 1 - 4
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 9 9 5 2 2 - 1
Transcription and Translation in Health and Disease provides a detailed overview of the regulators underlying transcription and translation in relation to a variety of human… Read more
Purchase Options
Transcription and Translation in Health and Disease provides a detailed overview of the regulators underlying transcription and translation in relation to a variety of human diseases and disorders. Beginning with an introduction into the current perspectives relating to these processes in human disease, the book expands to focus on specific mechanisms underlying conditions such as arthritis, cancer, neurological disorders, diabetes and cardiovascular disease. This book considers RNA processing and related mechanisms in eukaryotes including RNA splicing, RNA binding proteins, RNA interference, microRNAs, RNA editing, transcription factors, RNAi screening, CRISPR activation, CRISPR-Cas9 interference, and post-translational modifications.
It provides a structured and detailed overview of the various regulators underlying molecular processes and their impact on health and disease, equipping readers with the necessary knowledge for further investigation in the areas of treatment and therapeutic intervention.
- Discusses the role played by transcription and translational regulation in various diseases, including cancer, diabetes, cardiovascular disease and neurological disease
- Considers a range of post-transcriptional regulators, including RNA-binding proteins, non-coding RNAs, epigenetic modifiers, alternative splicing and telomerase-binding proteins
- Covers the topic from fundamental knowledge to the latest developments in clinical application
- Includes a section dedicated to therapeutic applications
Researchers in molecular biology, biochemistry, cell biology, genetics, microbiology, biotechnology, and pharma / therapeutics, Undergraduate and postgraduate students in related fields
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- About the editors
- Preface
- Section I: Introduction
- Chapter 1: Current perspective of transcriptional regulators in human health and diseases
- Abstract
- Introduction
- Key transcriptional regulators and their critical role in regulating the transcription
- Dysregulation of transcriptional regulators in diabetes
- Dysregulation of transcriptional regulators in human cancers
- Misregulation of transcription factors (TFs) and mediator coactivation complex
- References
- Section II: Transcriptional and translational regulators in cancer
- Chapter 2: Role of alternative splicing in health and diseases
- Abstract
- Introduction
- Splicing and alternative splicing
- Alternative splicing in disease
- References
- Chapter 3: Role of transcriptional and posttranscriptional regulation of sphingolipid genes in molecular heterogeneity of breast cancer
- Abstract
- Introduction to sphingolipids
- Breast cancer heterogeneity
- Sphingolipid gene expression in different subtypes of breast cancer
- Molecular mechanisms by which sphingolipids regulate gene expression in signaling cascades
- Posttranscriptional modifications
- References
- Chapter 4: Who dictates and when: Genetic and epigenetic dictatorships in breast cancer response and resistance to therapy
- Abstract
- Introduction
- Breast cancer subtypes
- Breast cancer treatment
- Response to therapy and drug resistance
- Genetic vs epigenetic dictators
- References
- Chapter 5: Cross-talk between NF-κB and telomerase in cancer: Implications in therapy
- Abstract
- Introduction
- Regulation of telomerase by NF-κB in cancer
- Regulation of NF-κB activity by telomerase
- Implications in cancer therapy and future directions
- References
- Chapter 6: Genome editing and regulation of transcription and translational using CRISPR-Cas9 system
- Abstract
- Central dogma of molecular biology
- Intervention of central dogma: Correcting errors in genetic diseases by gene editing
- Gene editing by CRISPR-Cas9 system
- Examples of CRISPR-Cas9-based gene editing in vitro and in vivo
- Nobel Prize 2020
- References
- Chapter 7: Regulation of posttranscriptional events by RNA-binding proteins
- Abstract
- Acknowledgment
- Introduction
- Dysregulation of RBPs involved in posttranscriptional regulation
- Nascent mRNA bound proteins in cancer
- Cap-binding proteins in cancer
- Splicing associated proteins in cancer
- Poly(A) tail and alternative polyadenylation-dependent proteins in cancer
- Modified base recognizing proteins in cancer
- mRNPs involved in nuclear export and their role in cancer
- mRNPs involved in subcellular localization and their role in cancer
- mRNPs in translation and cancer
- mRNP stability and cancer
- Conclusions
- References
- Chapter 8: The language of posttranslational modifications and deciphering it from proteomics data
- Abstract
- Conflict of interest
- Author contributions
- Introduction
- PTMs in cancer
- PTM cross-talks are prevalent in health and disease
- PTMs in drug resistance
- PTMs and SNPs
- Shotgun proteomics for studying proteins and their modifications
- Data analysis for PTMs
- Functional analysis of protein mod-forms
- Conclusion
- References
- Section III: Transcriptional and translation regulators of other diseases
- Chapter 9: Noncoding RNAs in human health and diseases
- Abstract
- Introduction
- Noncoding RNA
- Types of noncoding RNA
- Role of noncoding RNAs in diseases
- Role of ncRNAs in diabetes
- Conclusion
- Perspectives and future directions
- References
- Chapter 10: MiRNAs as epigenetic regulators for gut microbiome
- Abstract
- Introduction
- MicroRNA discovery and biogenesis
- Gene regulation by miRNAs
- miRNAs in host immune system
- Gut microbiome—As a regulator of wellness and diseases
- Microbiota-miRNA interplay to influence gene expression
- Epithelial cell microRNAs in gut immunity
- Gut microbiome—miRNA And human diseases
- Concluding comments and future viewpoints
- References
- Chapter 11: Crosstalk between microRNAs and epigenetics during brain development and neurological diseases
- Abstract
- Acknowledgments
- Introduction
- Epigenetic changes
- Neural development and miRNAs
- Neural development and epigenetics
- Neurodevelopmental disorders
- Neurodegenerative diseases
- Conclusion
- References
- Chapter 12: Implications of miRNA in autoimmune and inflammatory skin diseases
- Abstract
- Introduction
- Structure of the human skin
- Micro-RNAs and its biogenesis
- miRNA and skin diseases
- Emerging miRNA-based drugs
- References
- Chapter 13: Micro-RNA contribution to angiogenesis in cancer
- Abstract
- Introduction
- miRNA-190
- miRNA-29b
- miRNA-6086
- miRNA-378a-5p
- miRNA-221-3p
- Conclusion
- References
- Chapter 14: Emerging role of mRNA and RNA binding proteins in Diabetes
- Abstract
- Introduction
- RNA binding proteins
- RBPs at the crossroad of diabetes mellitus
- Posttranscriptional modifications in diabetes
- RNA-based therapeutics for diabetes
- Conclusion
- References
- Chapter 15: Caenorhabditis elegans: An interesting host for aging-related studies
- Abstract
- Acknowledgment
- An overview of the oxidative stress theory of aging
- Oxidative stress and age-associated diseases
- The beneficial properties of the CE-based model for in vitro studies
- Natural products used in the CE model for aging-related studies
- CE model used in antioxidant study
- CE model in the antiaging study
- Limitations of the CE-based model
- Conclusion and future directions
- References
- Chapter 16: The role of LncRNA and micro-RNA targeting GLI transcription factors in human cancers
- Abstract
- Overview of GLI proteins
- GLI as a nuclear executor of the hedgehog (Hh) signaling pathway
- Long noncoding RNA as a potential regulator of GLI activity
- miRNA as a potential regulator of GLI activity
- References
- Section IV: Therapeutics
- Chapter 17: Inhibitors targeting epigenetic modifications in cancer
- Abstract
- Conflict of interests
- Introduction
- Mechanism of epigenetic regulation
- Epigenetic regulation in cancer
- Epigenetic diagnostic biomarkers in various cancers
- Epigenetic targets for cancer treatment
- Conclusion
- Glossary
- References
- Chapter 18: Modulation of epigenetic methylation enzymes by synthetic and natural agents
- Abstract
- Introduction
- DNA methylation in cancer
- Histone lysine methylation in cancer
- PR domain-containing genes with zinc fingers (PRDMs)
- Mixed lineage leukemia
- Nuclear receptor binding Su (var)3–9, enhancer of zeste, and trithorax domain protein 1
- Enhancer of Zeste 2 homolog Polycomb repressive complex
- SET and MYND domain proteins
- Role of histone lysine demethylases in cancer
- Lysine-specific histone demethylase 1
- JmjC domain-containing demethylase GASC1 (JMJD2C)
- Jumonji, AT-rich interactive domain demethylase Plu-1 (JARID1B)
- Retinoblastoma binding protein 2 (RBP2)
- Histone arginine methyltransferases
- Histone lysine methylase and demethylase inhibitors in cancer
- Natural products and their semisynthetic derivatives as the inhibitors of epigenetic enzymes (methylase and demethylase)
- Conclusion and future perspectives
- References
- Chapter 19: Transcriptional regulatory network associated with multiple sclerosis pathogenesis
- Abstract
- Introduction
- Conclusion
- References
- Chapter 20: Role of adipokines in the pathophysiology of coronary artery disease
- Abstract
- Conflict of interest
- Introduction
- Risk factors for coronary artery disease
- Role of Adipokines in the development of CAD
- Role of glucocorticoids in coronary artery disease
- References
- Index
- No. of pages: 416
- Language: English
- Published: January 30, 2023
- Imprint: Academic Press
- Paperback ISBN: 9780323995214
- eBook ISBN: 9780323995221
MG
Manoj Garg
Dr. Manoj Garg completed his PhD at the National Institute of Immunology (NII), New Delhi and University of Rajasthan, Jaipur, India. He joined as a Research Scientist at the Cancer Science Institute (CSI), National University of Singapore, Singapore in 2010 and extensively worked on cutting-edge technologies including next‐generation sequencing of both DNA and RNA, shRNA library screening, drug screening in different subtypes of Acute myeloid leukemia (AML), Acute Lymphocytic leukemia (ALL), esophageal squamous cell carcinoma, pancreatic carcinoma, anaplastic thyroid carcinoma, and liposarcoma. In 2016, Dr. Garg was awarded Ramalingaswami Fellowship and returned to India and joined as an Assistant Professor at Cancer Institute, Chennai. He received the Early Career Research Award from Science Engineering and Research Board (SERB), GOI in 2017. Dr. Garg has published his research in a range of well‐reputed scientific journals and serves as an editor for various international journal.
Affiliations and expertise
Associate Professor, Amity Institute of Molecular Medicine and Stem Cell Research (AIMMSCR), Amity University, Noida, IndiaGS
Gautam Sethi
Dr. Gautam Sethi is a tenured Associate Professor in Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore. The focus of his research over the past few years has been to elucidate the mechanism (s) of activation of oncogenic transcription factors by carcinogens and inflammatory agents and the identification of novel inhibitors of these proteins for prevention of and therapy for cancer. The findings of his research work have so far resulted in more than three hundred and fifty scientific publications in high impact factor peer reviewed journals (with h index = 109) and several international awards. He also serves as an editorial board member for over more than 15 international journals
Affiliations and expertise
Associate Professor, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, SingaporeAP
Amit Kumar Pandey
Dr. Amit Kumar Pandey completed his postdoctoral training at the Cancer Science Institute of Singapore, National University of Singapore, Singapore where he worked on exploring the role of miRNAs in epigenetic regulation of metastatic breast cancer, and Max Delbruck Center for Molecular Medicine, Berlin, Germany where he worked on exploring the role of non-coding RNAs in metabolism. Dr. Pandey has been working in the field of non-coding RNAs for the last 12 years. He has worked extensively in molecular and cell biology, cell signaling, next generation sequencing. For the last 3 years Dr. Pandey has been working as Assistant professor and running 4 research grants from various govt. agencies as principal investigator. Dr. Pandey currently serves as editor of PLOS One and review editor of Frontiers in Molecular Biosciences.
Affiliations and expertise
Assistant Professor, Amity Institute of Biotechnology, Amity University Haryana, India